Moderna’s expanding pipeline beyond its Covid‑19 vaccine is drawing fresh attention from investors, after a recent appearance on a financial news program.
Market reaction and recent performance
The stock has risen almost 150% so far this year, making it one of the S&P 500’s top performers. Unlike many other high‑flying shares, gains are not tied to the artificial‑intelligence infrastructure surge. Despite the rally, the price remains well under the August 2021 peak of $484, which was reached when the Covid vaccine drove record revenue.
During a segment on “Mad Money,” the host urged investors to be patient, suggesting a pullback could present a better entry point. “Take your time,” he said, adding that the future looks promising but will unfold over several years.
New products and profitability outlook
At the recent Science Day, executives outlined a roadmap that extends through the next decade. The plan highlights a growing oncology portfolio and additional vaccine programs that move the firm beyond its pandemic‑era focus.
Related: Rates cut for music and nightlife venues
In particular, Moderna now has cancer therapies in mid‑ and late‑stage trials for melanoma, non‑small cell lung cancer, renal cell carcinoma, and bladder cancer. A late‑stage study of an individualized therapy, known as intismeran, is expected to report results later this year. This treatment is being developed jointly with Merck and is designed to work alongside Merck’s Keytruda as a secondary option for melanoma patients.
The host noted that the emphasis on oncology marks a shift for a company seeking new revenue streams after Covid vaccine demand waned. “Moderna has a range of new products and a roadmap to profitability for the first time in such a long time,” he said.
In addition to cancer work, the pipeline includes a flu vaccine that recently received a favorable recommendation from an FDA advisory committee. The European Commission also approved a combined Covid‑19 and flu vaccine earlier this year, indicating progress on non‑Covid products.
Investors who have been waiting for a catalyst may find the diversified pipeline appealing. The shift toward oncology and flu vaccines could reduce reliance on a single product line, potentially stabilizing earnings over the long term.
Related: HR Outsourcing Costs Benefits for Small Businesses 2026
While optimism is evident, valuation still reflects uncertainty. Revenue from the Covid vaccine has declined as global demand decreased, and the success of new products remains to be proven in the market.
Analysts point out that the timeline for profitability may be longer than some investors hope. Development and regulatory approval processes for cancer therapies, especially personalized treatments like intismeran, can extend over several years.
Nevertheless, the recent rally of roughly 20% since the Science Day event suggests that market participants are beginning to price in the potential of these initiatives. The ability to translate the research pipeline into commercial products will be the key test in the coming quarters.
